Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration
To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops. A total of 510 subjects (...
Saved in:
| Published in | Ophthalmology (Rochester, Minn.) Vol. 122; no. 3; pp. 579 - 588 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.03.2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops.
A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti–vascular endothelial growth factor intravitreal injections.
Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n = 73); pazopanib 5 mg/ml instilled 3 (n = 72) or 4 times daily (n = 74); pazopanib 10 mg/ml instilled 2 (n = 73), 3 (n = 73), or 4 times daily (n = 72); or ranibizumab injection administered once every 4 weeks (n = 73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed.
The main outcome measures were best-corrected visual acuity (BCVA) and injection frequency assessed at week 52. Safety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24.
At week 52, pazopanib, with allowance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0.3–1.8 vs. 1.4 vs. 0.2 letters, respectively). Pazopanib treatment did not reduce as-needed ranibizumab injections by ≥50% (prespecified efficacy criterion). At week 52, there were no clinically meaningful changes from baseline in retinal thickness or morphology, CNV size, or lesion characteristics on optical coherence tomography or fluorescein angiography. Complement factor H genotype had no effect on the responses to pazopanib and/or ranibizumab (BCVA, injection rate, or optical coherence tomography/fluorescein angiography changes). Steady-state concentrations of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported.
Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone. |
|---|---|
| AbstractList | Purpose To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops. Participants A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti–vascular endothelial growth factor intravitreal injections. Methods Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n = 73); pazopanib 5 mg/ml instilled 3 (n = 72) or 4 times daily (n = 74); pazopanib 10 mg/ml instilled 2 (n = 73), 3 (n = 73), or 4 times daily (n = 72); or ranibizumab injection administered once every 4 weeks (n = 73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed. Main Outcome Measures The main outcome measures were best-corrected visual acuity (BCVA) and injection frequency assessed at week 52. Safety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24. Results At week 52, pazopanib, with allowance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0.3–1.8 vs. 1.4 vs. 0.2 letters, respectively). Pazopanib treatment did not reduce as-needed ranibizumab injections by ≥50% (prespecified efficacy criterion). At week 52, there were no clinically meaningful changes from baseline in retinal thickness or morphology, CNV size, or lesion characteristics on optical coherence tomography or fluorescein angiography. Complement factor H genotype had no effect on the responses to pazopanib and/or ranibizumab (BCVA, injection rate, or optical coherence tomography/fluorescein angiography changes). Steady-state concentrations of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported. Conclusions Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone. To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops. A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti–vascular endothelial growth factor intravitreal injections. Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n = 73); pazopanib 5 mg/ml instilled 3 (n = 72) or 4 times daily (n = 74); pazopanib 10 mg/ml instilled 2 (n = 73), 3 (n = 73), or 4 times daily (n = 72); or ranibizumab injection administered once every 4 weeks (n = 73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed. The main outcome measures were best-corrected visual acuity (BCVA) and injection frequency assessed at week 52. Safety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24. At week 52, pazopanib, with allowance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0.3–1.8 vs. 1.4 vs. 0.2 letters, respectively). Pazopanib treatment did not reduce as-needed ranibizumab injections by ≥50% (prespecified efficacy criterion). At week 52, there were no clinically meaningful changes from baseline in retinal thickness or morphology, CNV size, or lesion characteristics on optical coherence tomography or fluorescein angiography. Complement factor H genotype had no effect on the responses to pazopanib and/or ranibizumab (BCVA, injection rate, or optical coherence tomography/fluorescein angiography changes). Steady-state concentrations of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported. Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone. To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops. A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti-vascular endothelial growth factor intravitreal injections. Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n=73); pazopanib 5 mg/ml instilled 3 (n=72) or 4 times daily (n=74); pazopanib 10 mg/ml instilled 2 (n=73), 3 (n=73), or 4 times daily (n=72); or ranibizumab injection administered once every 4 weeks (n=73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed. The main outcome measures were best-corrected visual acuity (BCVA) and injection frequency assessed at week 52. Safety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24. At week 52, pazopanib, with allowance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0.3-1.8 vs. 1.4 vs. 0.2 letters, respectively). Pazopanib treatment did not reduce as-needed ranibizumab injections by ≥50% (prespecified efficacy criterion). At week 52, there were no clinically meaningful changes from baseline in retinal thickness or morphology, CNV size, or lesion characteristics on optical coherence tomography or fluorescein angiography. Complement factor H genotype had no effect on the responses to pazopanib and/or ranibizumab (BCVA, injection rate, or optical coherence tomography/fluorescein angiography changes). Steady-state concentrations of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported. Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone. To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).PURPOSETo evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops.DESIGNMulticountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops.A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti-vascular endothelial growth factor intravitreal injections.PARTICIPANTSA total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti-vascular endothelial growth factor intravitreal injections.Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n=73); pazopanib 5 mg/ml instilled 3 (n=72) or 4 times daily (n=74); pazopanib 10 mg/ml instilled 2 (n=73), 3 (n=73), or 4 times daily (n=72); or ranibizumab injection administered once every 4 weeks (n=73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed.METHODSTreatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n=73); pazopanib 5 mg/ml instilled 3 (n=72) or 4 times daily (n=74); pazopanib 10 mg/ml instilled 2 (n=73), 3 (n=73), or 4 times daily (n=72); or ranibizumab injection administered once every 4 weeks (n=73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed.The main outcome measures were best-corrected visual acuity (BCVA) and injection frequency assessed at week 52. Safety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24.MAIN OUTCOME MEASURESThe main outcome measures were best-corrected visual acuity (BCVA) and injection frequency assessed at week 52. Safety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24.At week 52, pazopanib, with allowance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0.3-1.8 vs. 1.4 vs. 0.2 letters, respectively). Pazopanib treatment did not reduce as-needed ranibizumab injections by ≥50% (prespecified efficacy criterion). At week 52, there were no clinically meaningful changes from baseline in retinal thickness or morphology, CNV size, or lesion characteristics on optical coherence tomography or fluorescein angiography. Complement factor H genotype had no effect on the responses to pazopanib and/or ranibizumab (BCVA, injection rate, or optical coherence tomography/fluorescein angiography changes). Steady-state concentrations of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported.RESULTSAt week 52, pazopanib, with allowance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0.3-1.8 vs. 1.4 vs. 0.2 letters, respectively). Pazopanib treatment did not reduce as-needed ranibizumab injections by ≥50% (prespecified efficacy criterion). At week 52, there were no clinically meaningful changes from baseline in retinal thickness or morphology, CNV size, or lesion characteristics on optical coherence tomography or fluorescein angiography. Complement factor H genotype had no effect on the responses to pazopanib and/or ranibizumab (BCVA, injection rate, or optical coherence tomography/fluorescein angiography changes). Steady-state concentrations of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported.Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone.CONCLUSIONSPazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone. |
| Author | Dugel, Pravin U. Wurzelmann, John I. Kelly, Deborah S. Xu, Chun-Fang Fries, Michael A. Csaky, Karl G. Pierce, Amy J. Hossain, Mohammad Danis, Ronald P. Trivedi, Trupti |
| Author_xml | – sequence: 1 givenname: Karl G. surname: Csaky fullname: Csaky, Karl G. organization: Retina Foundation of the Southwest, Dallas, Texas – sequence: 2 givenname: Pravin U. surname: Dugel fullname: Dugel, Pravin U. organization: Retinal Consultants of Arizona, Phoenix, Arizona – sequence: 3 givenname: Amy J. surname: Pierce fullname: Pierce, Amy J. organization: GlaxoSmithKline, King of Prussia, Pennsylvania – sequence: 4 givenname: Michael A. surname: Fries fullname: Fries, Michael A. organization: GlaxoSmithKline, King of Prussia, Pennsylvania – sequence: 5 givenname: Deborah S. surname: Kelly fullname: Kelly, Deborah S. organization: GlaxoSmithKline, King of Prussia, Pennsylvania – sequence: 6 givenname: Ronald P. surname: Danis fullname: Danis, Ronald P. organization: Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin – sequence: 7 givenname: John I. surname: Wurzelmann fullname: Wurzelmann, John I. email: wurzelma@gmail.com organization: GlaxoSmithKline, King of Prussia, Pennsylvania – sequence: 8 givenname: Chun-Fang surname: Xu fullname: Xu, Chun-Fang organization: GlaxoSmithKline, King of Prussia, Pennsylvania – sequence: 9 givenname: Mohammad surname: Hossain fullname: Hossain, Mohammad organization: GlaxoSmithKline, King of Prussia, Pennsylvania – sequence: 10 givenname: Trupti surname: Trivedi fullname: Trivedi, Trupti organization: GlaxoSmithKline, King of Prussia, Pennsylvania |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25432081$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUl1v0zAUtdAQ6wb_ACE_8pJgO44bI4Q0dWVUGh_a4Nly3JvVJbU7Oynq_sb-MM7SvSChiSfrXp1zrnzOOUFHzjtA6DUlOSVUvFvnfrvqVjpnhPKcyJwU4hma0JLLjE9pcYQmCUYzwRk5RicxrgkhQhT8BTpmJS8YqegE3c9a66zRLZ7vdNvrznqHfYO_6zu_1c7WeL4HfB78NuIdhNhHfDWs7V2_0TVeuC7one0CJIWFW4MZBCK2Dl_39TBG_Nt2K_wV_E5H07c64LMbyK6g1R0s8Rc97s7hBhyEh_sv0fNGtxFeHd5T9PPT_Mfsc3b57WIxO7vMDJeiy5ppSSotSlmApqyuYUorkLXRzZKKgjBJ67qRRFNtGsGaaV2JNBkmq7RrKlqcorej7jb42x5ipzY2Gmhb7cD3UVFRVpyVRTVN0DcHaF9vYKm2wW502KtHIxPg_QgwwccYoFHGdg-_SQbZVlGihtTUWo2pqSE1RaRKqSUy_4v8qP8E7eNIg2TSzkJQ0VhwBpY2JOfV0tv_FTCHNvyCPcS174NLASiqIlNEXQ99GupEOSGSs8GWD_8WePr-H_M132c |
| CitedBy_id | crossref_primary_10_1167_tvst_13_8_24 crossref_primary_10_1016_j_jconrel_2019_07_020 crossref_primary_10_1016_j_ajo_2022_02_019 crossref_primary_10_1016_j_biopha_2022_112911 crossref_primary_10_1007_s12272_024_01503_3 crossref_primary_10_1167_tvst_10_14_23 crossref_primary_10_1080_14728214_2017_1362390 crossref_primary_10_1038_s41433_023_02610_z crossref_primary_10_1167_iovs_65_12_14 crossref_primary_10_1080_14656566_2019_1636031 crossref_primary_10_1016_j_preteyeres_2024_101243 crossref_primary_10_1002_14651858_CD005139_pub4 crossref_primary_10_1111_aos_14756 crossref_primary_10_3390_molecules27165089 crossref_primary_10_3389_fbioe_2023_1199922 crossref_primary_10_1016_j_oftal_2019_09_011 crossref_primary_10_3390_pharmaceutics14010134 crossref_primary_10_1159_000514441 crossref_primary_10_1016_j_xops_2022_100163 crossref_primary_10_1080_14728214_2023_2259790 crossref_primary_10_1136_bmjopen_2020_040906 crossref_primary_10_1111_bph_15459 crossref_primary_10_3390_pharmaceutics12121174 crossref_primary_10_1016_S0140_6736_18_31550_2 crossref_primary_10_1016_j_oftale_2019_09_013 crossref_primary_10_1080_17425247_2016_1213240 crossref_primary_10_1167_iovs_66_1_47 crossref_primary_10_1136_bjophthalmol_2018_313462 crossref_primary_10_1016_j_oret_2017_04_004 crossref_primary_10_1167_tvst_10_7_19 crossref_primary_10_2147_DDDT_S295223 crossref_primary_10_1007_s40265_021_01507_z crossref_primary_10_1002_prp2_545 crossref_primary_10_1021_acs_jmedchem_7b01731 crossref_primary_10_1186_s40942_021_00325_5 crossref_primary_10_1007_s40123_021_00365_y crossref_primary_10_3341_jkos_2019_60_5_491 crossref_primary_10_1111_bcp_13794 crossref_primary_10_1080_14656566_2024_2354921 crossref_primary_10_1016_j_addr_2023_114965 crossref_primary_10_3928_23258160_20201104_01 crossref_primary_10_1111_ceo_13333 crossref_primary_10_1155_2017_6145651 crossref_primary_10_1517_14656566_2015_1067679 crossref_primary_10_18008_1816_5095_2022_1_22_32 crossref_primary_10_1126_sciadv_adi5501 crossref_primary_10_1002_advs_202407340 crossref_primary_10_1016_j_ijpharm_2021_120272 crossref_primary_10_1177_1120672118802541 crossref_primary_10_1097_ICU_0000000000000147 crossref_primary_10_1016_j_jconrel_2017_09_036 crossref_primary_10_1016_j_addr_2024_115321 crossref_primary_10_3390_life13020568 crossref_primary_10_1021_acsami_2c17626 |
| Cites_doi | 10.1136/bjophthalmol-2013-303117 10.1136/bjo.2008.150995 10.1016/j.ophtha.2012.05.040 10.1371/journal.pone.0042464 10.1016/j.ophtha.2007.09.008 10.1056/NEJMoa1102673 10.1056/NEJMra0801537 10.1016/j.ophtha.2013.01.057 10.1016/j.ophtha.2012.03.053 10.1016/j.ajo.2012.10.018 10.1001/archophthalmol.2009.27 10.1001/archopht.122.4.598 10.1097/01.iae.0000242842.14624.e7 10.1016/j.ophtha.2008.10.018 10.1016/j.ejphar.2011.05.016 10.1126/science.1109557 10.1016/j.ajo.2007.01.028 10.1016/j.ophtha.2012.11.037 10.1155/2013/830837 10.1016/j.ophtha.2010.12.019 10.1167/iovs.07-1132 10.1056/NEJMoa054481 10.1056/NEJMoa062655 10.1158/1535-7163.MCT-07-0193 10.1016/j.ophtha.2012.04.015 10.1056/NEJM200002173420707 10.1126/science.1110189 |
| ContentType | Journal Article |
| Copyright | 2015 American Academy of Ophthalmology American Academy of Ophthalmology Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2015 American Academy of Ophthalmology – notice: American Academy of Ophthalmology – notice: Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ophtha.2014.09.036 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1549-4713 |
| EndPage | 588 |
| ExternalDocumentID | 25432081 10_1016_j_ophtha_2014_09_036 S0161642014009427 1_s2_0_S0161642014009427 |
| Genre | Multicenter Study Clinical Trial, Phase II Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Genentech – fundername: GlaxoSmithKline (GSK) |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1B1 1CY 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ACVFH ADCNI ADMUD ADNMO AEFWE AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGQPQ AIGII AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CS3 DU5 EBS EFJIC EFKBS EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NQ- O9- OF- OPF OQ~ P2P R2- ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP ADPAM RIG AAIAV AGZHU AHPSJ ALXNB ZA5 AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c496t-f7508a6593ea12bbe718e9bcafd1630291bbf90a1acf62f7b8690ac2980a1f813 |
| ISSN | 0161-6420 1549-4713 |
| IngestDate | Thu Jul 10 23:57:31 EDT 2025 Mon Jul 21 06:08:48 EDT 2025 Tue Jul 01 03:37:58 EDT 2025 Thu Apr 24 23:07:46 EDT 2025 Fri Feb 23 02:14:13 EST 2024 Sun Feb 23 10:19:57 EST 2025 Tue Aug 26 16:37:02 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | OCT AE CFH CI IVT VEGF IR CNV VA QID PED TID BCVA SAE AMD FA PK SR fluorescein angiography optical coherence tomography 4 times daily serious adverse event subretinal pharmacokinetic age-related macular degeneration choroidal neovascularization visual acuity adverse event 3 times daily vascular endothelial growth factor best-corrected visual acuity intravitreal confidence interval intraretinal pigment epithelial detachment complement factor H |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c496t-f7508a6593ea12bbe718e9bcafd1630291bbf90a1acf62f7b8690ac2980a1f813 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 25432081 |
| PQID | 1658425387 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1658425387 pubmed_primary_25432081 crossref_citationtrail_10_1016_j_ophtha_2014_09_036 crossref_primary_10_1016_j_ophtha_2014_09_036 elsevier_sciencedirect_doi_10_1016_j_ophtha_2014_09_036 elsevier_clinicalkeyesjournals_1_s2_0_S0161642014009427 elsevier_clinicalkey_doi_10_1016_j_ophtha_2014_09_036 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-03-01 |
| PublicationDateYYYYMMDD | 2015-03-01 |
| PublicationDate_xml | – month: 03 year: 2015 text: 2015-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Ophthalmology (Rochester, Minn.) |
| PublicationTitleAlternate | Ophthalmology |
| PublicationYear | 2015 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Group, Martin, Maguire (bib28) 2011; 364 Klein, Zeiss, Chew (bib22) 2005; 308 Lee, Raya, Kymes (bib25) 2009; 93 Yafai, Yang, Niemeyer (bib13) 2011; 666 Jager, Mieler, Miller (bib9) 2008; 358 Hanout, Ferraz, Ansari (bib5) 2013; 2013 Rosenfeld, Brown, Heier (bib7) 2006; 355 Csaky, Richman, Ferris (bib18) 2008; 49 Kumar, Knick, Rudolph (bib11) 2007; 6 Hagstrom, Ying, Pauer (bib27) 2013; 120 Edwards, Ritter, Abel (bib21) 2005; 308 Martin, Maguire, Fine (bib8) 2012; 119 Ferrara, Damico, Shams (bib4) 2006; 26 Miller (bib1) 2013; 155 Chen, Yu, Xu (bib24) 2012; 7 Takahashi, Saishin, Saishin (bib12) 2009; 127 Investigators, Chakravarthy, Harding (bib19) 2012; 119 Smailhodzic, Muether, Chen (bib26) 2012; 119 Ho, Yue, Wilson (bib17) 2008; 49 Danis, McLaughlin, Tolentino (bib14) 2014; 98 Zarbin (bib3) 2004; 122 Holz, Amoaku, Donate (bib16) 2011; 118 Brantley, Fang, King (bib23) 2007; 114 Brown, Michels, Kaiser (bib6) 2009; 116 Fine, Berger, Maguire, Ho (bib2) 2000; 342 Fung, Lalwani, Rosenfeld (bib15) 2007; 143 Brown, Kaiser, Michels (bib20) 2006; 355 Haller (bib10) 2013; 120 Fung (10.1016/j.ophtha.2014.09.036_bib15) 2007; 143 Miller (10.1016/j.ophtha.2014.09.036_bib1) 2013; 155 Zarbin (10.1016/j.ophtha.2014.09.036_bib3) 2004; 122 Brown (10.1016/j.ophtha.2014.09.036_bib20) 2006; 355 Kumar (10.1016/j.ophtha.2014.09.036_bib11) 2007; 6 Fine (10.1016/j.ophtha.2014.09.036_bib2) 2000; 342 Holz (10.1016/j.ophtha.2014.09.036_bib16) 2011; 118 Danis (10.1016/j.ophtha.2014.09.036_bib14) 2014; 98 Hanout (10.1016/j.ophtha.2014.09.036_bib5) 2013; 2013 Ferrara (10.1016/j.ophtha.2014.09.036_bib4) 2006; 26 Smailhodzic (10.1016/j.ophtha.2014.09.036_bib26) 2012; 119 Hagstrom (10.1016/j.ophtha.2014.09.036_bib27) 2013; 120 Edwards (10.1016/j.ophtha.2014.09.036_bib21) 2005; 308 Takahashi (10.1016/j.ophtha.2014.09.036_bib12) 2009; 127 Haller (10.1016/j.ophtha.2014.09.036_bib10) 2013; 120 Brantley (10.1016/j.ophtha.2014.09.036_bib23) 2007; 114 Rosenfeld (10.1016/j.ophtha.2014.09.036_bib7) 2006; 355 Chen (10.1016/j.ophtha.2014.09.036_bib24) 2012; 7 Investigators (10.1016/j.ophtha.2014.09.036_bib19) 2012; 119 Yafai (10.1016/j.ophtha.2014.09.036_bib13) 2011; 666 Brown (10.1016/j.ophtha.2014.09.036_bib6) 2009; 116 Lee (10.1016/j.ophtha.2014.09.036_bib25) 2009; 93 Group (10.1016/j.ophtha.2014.09.036_bib28) 2011; 364 Martin (10.1016/j.ophtha.2014.09.036_bib8) 2012; 119 Klein (10.1016/j.ophtha.2014.09.036_bib22) 2005; 308 Csaky (10.1016/j.ophtha.2014.09.036_bib18) 2008; 49 Jager (10.1016/j.ophtha.2014.09.036_bib9) 2008; 358 Ho (10.1016/j.ophtha.2014.09.036_bib17) 2008; 49 |
| References_xml | – volume: 6 start-page: 2012 year: 2007 end-page: 2021 ident: bib11 article-title: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity publication-title: Mol Cancer Ther – volume: 358 start-page: 2606 year: 2008 end-page: 2617 ident: bib9 article-title: Age-related macular degeneration publication-title: N Engl J Med – volume: 666 start-page: 12 year: 2011 end-page: 18 ident: bib13 article-title: Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats publication-title: Eur J Pharmacol – volume: 114 start-page: 2168 year: 2007 end-page: 2173 ident: bib23 article-title: Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab publication-title: Ophthalmology – volume: 308 start-page: 385 year: 2005 end-page: 389 ident: bib22 article-title: Complement factor H polymorphism in age-related macular degeneration publication-title: Science – volume: 2013 start-page: 830837 year: 2013 ident: bib5 article-title: Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development publication-title: BioMed Res Int – volume: 355 start-page: 1419 year: 2006 end-page: 1431 ident: bib7 article-title: Ranibizumab for neovascular age-related macular degeneration publication-title: N Engl J Med – volume: 119 start-page: 1388 year: 2012 end-page: 1398 ident: bib8 article-title: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results publication-title: Ophthalmology – volume: 143 start-page: 566 year: 2007 end-page: 583 ident: bib15 article-title: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration publication-title: Am J Ophthalmol – volume: 49 year: 2008 ident: bib17 article-title: Ranibizumab in Wet Age-Related Macular Degeneration (AMD): crossover/rollover patient results in PIER study publication-title: Invest Ophthalmol Vis Sci – volume: 26 start-page: 859 year: 2006 end-page: 870 ident: bib4 article-title: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration publication-title: Retina – volume: 49 start-page: 479 year: 2008 end-page: 489 ident: bib18 article-title: Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium publication-title: Invest Ophthalmol Vis Sci – volume: 122 start-page: 598 year: 2004 end-page: 614 ident: bib3 article-title: Current concepts in the pathogenesis of age-related macular degeneration publication-title: Arch Ophthalmol – volume: 342 start-page: 483 year: 2000 end-page: 492 ident: bib2 article-title: Age-related macular degeneration publication-title: N Engl J Med – volume: 119 start-page: 1399 year: 2012 end-page: 1411 ident: bib19 article-title: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial publication-title: Ophthalmology – volume: 93 start-page: 610 year: 2009 end-page: 613 ident: bib25 article-title: Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab publication-title: Br J Ophthalmol – volume: 127 start-page: 494 year: 2009 end-page: 499 ident: bib12 article-title: Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib publication-title: Arch Ophthalmol – volume: 116 start-page: 57 year: 2009 end-page: 65.e5 ident: bib6 article-title: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study publication-title: Ophthalmology – volume: 364 start-page: 1897 year: 2011 end-page: 1908 ident: bib28 article-title: Ranibizumab and bevacizumab for neovascular age-related macular degeneration publication-title: N Engl J Med – volume: 120 start-page: 593 year: 2013 end-page: 599 ident: bib27 article-title: Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT) publication-title: Ophthalmology – volume: 155 start-page: 1 year: 2013 end-page: 35.e13 ident: bib1 article-title: Age-related macular degeneration revisited–piecing the puzzle: the LXIX Edward Jackson memorial lecture publication-title: Am J Ophthalmol – volume: 120 start-page: S3 year: 2013 end-page: S7 ident: bib10 article-title: Current anti-vascular endothelial growth factor dosing regimens: benefits and burden publication-title: Ophthalmology – volume: 118 start-page: 663 year: 2011 end-page: 671 ident: bib16 article-title: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study publication-title: Ophthalmology – volume: 308 start-page: 421 year: 2005 end-page: 424 ident: bib21 article-title: Complement factor H polymorphism and age-related macular degeneration publication-title: Science – volume: 98 start-page: 172 year: 2014 end-page: 178 ident: bib14 article-title: Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration publication-title: Br J Ophthalmol – volume: 7 start-page: e42464 year: 2012 ident: bib24 article-title: Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis publication-title: PloS One – volume: 119 start-page: 2304 year: 2012 end-page: 2311 ident: bib26 article-title: Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration publication-title: Ophthalmology – volume: 355 start-page: 1432 year: 2006 end-page: 1444 ident: bib20 article-title: Ranibizumab versus verteporfin for neovascular age-related macular degeneration publication-title: N Engl J Med – volume: 98 start-page: 172 year: 2014 ident: 10.1016/j.ophtha.2014.09.036_bib14 article-title: Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-303117 – volume: 93 start-page: 610 year: 2009 ident: 10.1016/j.ophtha.2014.09.036_bib25 article-title: Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab publication-title: Br J Ophthalmol doi: 10.1136/bjo.2008.150995 – volume: 119 start-page: 2304 year: 2012 ident: 10.1016/j.ophtha.2014.09.036_bib26 article-title: Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.05.040 – volume: 7 start-page: e42464 year: 2012 ident: 10.1016/j.ophtha.2014.09.036_bib24 article-title: Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis publication-title: PloS One doi: 10.1371/journal.pone.0042464 – volume: 114 start-page: 2168 year: 2007 ident: 10.1016/j.ophtha.2014.09.036_bib23 article-title: Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab publication-title: Ophthalmology doi: 10.1016/j.ophtha.2007.09.008 – volume: 364 start-page: 1897 year: 2011 ident: 10.1016/j.ophtha.2014.09.036_bib28 article-title: Ranibizumab and bevacizumab for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa1102673 – volume: 358 start-page: 2606 year: 2008 ident: 10.1016/j.ophtha.2014.09.036_bib9 article-title: Age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMra0801537 – volume: 120 start-page: S3 issue: 5 suppl year: 2013 ident: 10.1016/j.ophtha.2014.09.036_bib10 article-title: Current anti-vascular endothelial growth factor dosing regimens: benefits and burden publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.01.057 – volume: 119 start-page: 1388 year: 2012 ident: 10.1016/j.ophtha.2014.09.036_bib8 article-title: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.03.053 – volume: 155 start-page: 1 year: 2013 ident: 10.1016/j.ophtha.2014.09.036_bib1 article-title: Age-related macular degeneration revisited–piecing the puzzle: the LXIX Edward Jackson memorial lecture publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2012.10.018 – volume: 127 start-page: 494 year: 2009 ident: 10.1016/j.ophtha.2014.09.036_bib12 article-title: Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2009.27 – volume: 122 start-page: 598 year: 2004 ident: 10.1016/j.ophtha.2014.09.036_bib3 article-title: Current concepts in the pathogenesis of age-related macular degeneration publication-title: Arch Ophthalmol doi: 10.1001/archopht.122.4.598 – volume: 26 start-page: 859 year: 2006 ident: 10.1016/j.ophtha.2014.09.036_bib4 article-title: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration publication-title: Retina doi: 10.1097/01.iae.0000242842.14624.e7 – volume: 116 start-page: 57 year: 2009 ident: 10.1016/j.ophtha.2014.09.036_bib6 article-title: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.10.018 – volume: 666 start-page: 12 year: 2011 ident: 10.1016/j.ophtha.2014.09.036_bib13 article-title: Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2011.05.016 – volume: 308 start-page: 385 year: 2005 ident: 10.1016/j.ophtha.2014.09.036_bib22 article-title: Complement factor H polymorphism in age-related macular degeneration publication-title: Science doi: 10.1126/science.1109557 – volume: 143 start-page: 566 year: 2007 ident: 10.1016/j.ophtha.2014.09.036_bib15 article-title: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.01.028 – volume: 120 start-page: 593 year: 2013 ident: 10.1016/j.ophtha.2014.09.036_bib27 article-title: Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT) publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.11.037 – volume: 2013 start-page: 830837 year: 2013 ident: 10.1016/j.ophtha.2014.09.036_bib5 article-title: Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development publication-title: BioMed Res Int doi: 10.1155/2013/830837 – volume: 118 start-page: 663 year: 2011 ident: 10.1016/j.ophtha.2014.09.036_bib16 article-title: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.12.019 – volume: 49 start-page: 479 year: 2008 ident: 10.1016/j.ophtha.2014.09.036_bib18 article-title: Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.07-1132 – volume: 355 start-page: 1419 year: 2006 ident: 10.1016/j.ophtha.2014.09.036_bib7 article-title: Ranibizumab for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa054481 – volume: 355 start-page: 1432 year: 2006 ident: 10.1016/j.ophtha.2014.09.036_bib20 article-title: Ranibizumab versus verteporfin for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa062655 – volume: 49 year: 2008 ident: 10.1016/j.ophtha.2014.09.036_bib17 article-title: Ranibizumab in Wet Age-Related Macular Degeneration (AMD): crossover/rollover patient results in PIER study publication-title: Invest Ophthalmol Vis Sci – volume: 6 start-page: 2012 year: 2007 ident: 10.1016/j.ophtha.2014.09.036_bib11 article-title: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-07-0193 – volume: 119 start-page: 1399 year: 2012 ident: 10.1016/j.ophtha.2014.09.036_bib19 article-title: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.04.015 – volume: 342 start-page: 483 year: 2000 ident: 10.1016/j.ophtha.2014.09.036_bib2 article-title: Age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJM200002173420707 – volume: 308 start-page: 421 year: 2005 ident: 10.1016/j.ophtha.2014.09.036_bib21 article-title: Complement factor H polymorphism and age-related macular degeneration publication-title: Science doi: 10.1126/science.1110189 |
| SSID | ssj0006634 |
| Score | 2.4004345 |
| Snippet | To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).... Purpose To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration... To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 579 |
| SubjectTerms | Aged Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers - metabolism Double-Blind Method Female Fluorescein Angiography Humans Intravitreal Injections Male Neoplasm Proteins - genetics Ophthalmic Solutions Ophthalmology Pharmacogenetics Pyrimidines - adverse effects Pyrimidines - therapeutic use Ranibizumab Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Sulfonamides - adverse effects Sulfonamides - therapeutic use Tomography, Optical Coherence Visual Acuity Wet Macular Degeneration - drug therapy Wet Macular Degeneration - genetics Wet Macular Degeneration - physiopathology |
| Title | Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0161642014009427 https://www.clinicalkey.es/playcontent/1-s2.0-S0161642014009427 https://dx.doi.org/10.1016/j.ophtha.2014.09.036 https://www.ncbi.nlm.nih.gov/pubmed/25432081 https://www.proquest.com/docview/1658425387 |
| Volume | 122 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtpAEF1RIlV9qXpPetNW6ptlhBfbeB8RIY2CkkZRUPO22nXXBAQGYagUfqO_1Y_q7MX2tkmapC8WWrPryxxmZ4YzMwh9pknMk5AmfhqmsR8KGvtCSurzrpCEh1kkhcp3Pj6JD0fh0UV00Wj8clhLm7Vopdsb80r-R6owBnJVWbIPkGy1KAzAZ5AvHEHCcLyXjPtlWuOgqtmtOW18C65wPhHe4Ep6-6vFsvAU-2JTeGdqeLLdzLlQwcAV_zFRVHNVb2OqSVmGVw7qZKppHjpMeyJrwmpvLH1NoJOKn2HG9uVYF6-uZGyN3a_Ly_Uln81NmScdq7DtuQxhP89bTiCiX3ATxx3y1cz70qpN7LFhEpyqu829UXXmdKJYOVq7za-8o2r8QLn_Tk6A12u5wY0gqtldZbwzDnxwkdp_KGxCHGR2HPUbmcY0diePTMPAa5uEiVdMWwv9FhS9z9a6vaEm9197ZcVgLMlxU2ZWYWoV1qYMVnmEdgg4LaSJdnrDs2_DyjIA687WmjcPVaZyar7h9bu5zVS6zRXSJtH5M_TU-jK4Z4D5HDVk_gI9PrZsjZfoZ4lPXOMTLzJc4RMDPrHGJzb4xA4-sYtPXOMTT3Jc4hMrfGIHn9jBJ7b4xC4-X6HRweC8f-jbJiCgPWi89jMwaRMeR7QjeUCEkGBMSSpSnn0HV6JNaCBERts84GkWk6wrVIs1nhKawFiWBJ3XqJkvcrmLcKbr7YXKBSJhF86nNBJU1W_iMadxuIc65ftmqa2Qrxq1zNi_pL2H_GrW0lSIueP7USlKVmY_w37NAJ13zOveNE8WViEVLGAFYW3F14wDBa8gVLxh0nVnWrva2Mv3uOanEmsMth31XyLP5WID11KeCwFrCVZ_Y0BYPb2qr0HA1Xj7wDfzDj2pdcB71FyvNvIDmPxr8dH-kn4DtLYFug |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Evaluation+of+Pazopanib+Eye+Drops+versus+Ranibizumab+Intravitreal+Injections+in+Subjects+with+Neovascular+Age-Related+Macular+Degeneration&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Csaky%2C+Karl+G.&rft.au=Dugel%2C+Pravin+U.&rft.au=Pierce%2C+Amy+J.&rft.au=Fries%2C+Michael+A.&rft.date=2015-03-01&rft.issn=0161-6420&rft.volume=122&rft.issue=3&rft.spage=579&rft.epage=588&rft_id=info:doi/10.1016%2Fj.ophtha.2014.09.036&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ophtha_2014_09_036 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642014X00047%2Fcov150h.gif |